Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys

Research output: Contribution to journalArticleAcademicpeer-review

8 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys'. Together they form a unique fingerprint.

Medicine & Life Sciences